Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus

Abstract

This study was limited by the post hoc nature of the analysis and the small number of patients in the subgroup. However, the results suggest that linagliptin significantly improves glycemic control in Asian patients with T2DM inadequately controlled by basal insulin, without increasing the risk for hypoglycemia or weight gain. ClinicalTrials identifier: NCT00954447.

Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

“…Also, the proportion of patients with a reduction in HbA1c ≥ 0.5% was higher in the linagliptin group without an increase in hypoglycemia or body weight. Similar results were obtained in a post hoc analysis in the subset of Asian patients [ 25 ] as well as in a subanalysis of participants on basal insulin and also on metformin [ 26 ].…”

Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus

“…[22][23][24] Therefore, even though the study was not powered to assess potential differences between treatment arms in ethnic subgroups, if the numbers of patients were higher it is possible that statistically significant differences between treatment arms may have been evident in one or both subpopulations. Although the number of EA patients was small, the baseline clinical characteristics in this study were similar to those in other clinical trials conducted in EA patients.…”

“…Although the number of EA patients was small, the baseline clinical characteristics in this study were similar to those in other clinical trials conducted in EA patients. [22][23][24] Therefore, even though the study was not powered to assess potential differences between treatment arms in ethnic subgroups, if the numbers of patients were higher it is possible that statistically significant differences between treatment arms may have been evident in one or both subpopulations. Further, each country has varied clinical practice guidelines, prescribing practices, and dietary habits, which have the potential to cause bias in the analysis.…”

Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus

“…The DPP‐4 inhibitor linagliptin has been shown to improve glycaemic control and has a good tolerability profile, including low risk for hypoglycaemia and weight gain . When investigated specifically in older patients (aged ≥70 years) who were receiving metformin, SUs, basal insulin, or a combination of these drugs, linagliptin was effective in lowering blood glucose compared with placebo.…”